(MENAFN – ACN NewsWire) HOBOKEN, NJ , Rostock/Berlin, Germany, February 22, 2022 – (ACN Newswire) — Based on whole genome sequencing (WGS), Arcensus GmbH enables the detection of rare and common diseases such as cancer or Heart disease at its earliest stage to be able to start a preventive and personalized treatment.
A year after Arcensus was founded, fresh capital is now being raised for further expansion. As part of the current investment series, the Mittelständische Beteiligungsgesellschaft Mecklenburg-Vorpommern (MBMV) is investing a single-digit million amount in further expansion in the USA and the GCC region.
It is a very special investment for MBMV, as Managing Director Dr. Thomas Drews reveals: “With Arcensus, we are investing in a very experienced and renowned team and in a technology that, precisely in this combination, has the potential to make an important contribution to the prevention of diseases and the healing of rare diseases”.
He continues: ‘Moreover, we are proud that a local company from Rostock can play as a figurehead at the top of the international biotech scene.’
In fact, the team around Prof. Dr. Arndt Rolfs is no stranger to the biotech scene. Prof. Dr. Arndt Rolfs, a neurologist, took his rare disease company CENTOGENE, founded in 2006, to the stock exchange in 2019, in which MBMV also had a stake.
At Arcensus, Prof. Rolfs and his international team intend to use the accumulated experience in the field of WGS technology combined with a clear focus on the groundbreaking, artificial intelligence (AI)-based deep interpretation of DNA information to enable clients to best Insight into preventable diseases.
Prof. Rolfs commented on the investment as follows: ‘We are very pleased to have a well-known and extremely trustworthy partner at our side in MBMV, who shares our vision: to empower people with genomic and medical knowledge to understand and protect their health improve achieve a great and lasting quality of life and save lives”.
Arcensus is a digital health and diagnostics company that empowers people to take control of their health. The company offers a safe, trusted and comprehensive medical service of the highest quality based on whole genome sequencing. Arcensus analyzes the complete genetic information in the human DNA and uses the latest technology including artificial intelligence to identify the predispositions and reasons for unclear symptoms. The detailed medical report suggests better treatment options and helps individuals take preventive measures to live a healthier and longer life. From our offices in New Jersey (USA), Rostock and Berlin (Germany), a cross-functional team of genetic experts, physicians and data scientists work to bring the most sophisticated and best genetic interpretation with medical and preventive health applications to everyone. For more information visit .
About the medium-sized investment company Mecklenburg-Vorpommern (MBMV)
The Mittelstandische Beteiligungsgesellschaft Mecklenburg-Vorpommern mbH supports the promotion of regional SMEs by providing capital for the implementation of economic projects. It helps small and medium-sized companies in the region to consolidate or expand their market position. In particular, innovative companies with a national or international focus benefit from the flexible financing offer. For more information visit:
+49 1525 7692031
Important notice and disclaimer
This press release contains “forward-looking statements” within the meaning of the US federal securities laws. Statements contained herein that are not clearly historical in nature are forward-looking. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause Arcensus’ actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements . These risks and uncertainties include, but are not limited to, adverse global economic conditions and continued instability and volatility in global financial markets, the impact of the COVID-19 pandemic on our business and operating results, possible changes in current and proposed laws, regulations and government policies, pressure from increasing competition and consolidation in our industry, the cost and uncertainty of regulatory approvals, including the U.S. Food and Drug Administration, our dependence on third parties and collaborators, including our ability to manage growth and win new business relationships, our dependence on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, volatility in our operating results due to exchange rate effects, our ability to rationalize cash burn, our need for additional financing and our ability to continue as a going concern, or other factors.
This press release is distributed through Arab Newswire ( ) – a news service serving the Arab World, Middle East and North Africa (MENA) and is distributed by EmailWire(TM) ( ) – the global news service providing press release distribution with guaranteed results .
Disclaimer: MENAFN provides the information “as is” without any warranty of any kind. We assume no responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality or reliability of any information contained in this article. If you have any complaints or copyright issues related to this item, please contact the above vendor.